

ASX ANNOUNCEMENT

RESULTS OF THE ANNUAL GENERAL MEETING HELD ON FRIDAY 16 NOVEMBER 2012

Sydney, Australia, 16 November 2012: In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution on the agenda of this morning's Annual General Meeting.

Remuneration Report

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
210,452,900	26,137,728	2,024,591	50,145,514

The motion was carried as an ordinary resolution on a show of hands.

Re-election of Director - Mr Peter Francis

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
232,472,899	6,133,660	8,660	50,145,514

The motion was carried as an ordinary resolution on a show of hands.

Ratification of prior issue of shares

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
230,746,034	7,423,870	445,315	50,145,514

The motion was carried as an ordinary resolution on a show of hands.

For more information please contact:

Dr Peter French | Chief Executive Officer

Phone: +61 (02) 9555 6986 | pfrench@benitec.com | www.benitec.com

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX:BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi, also called expressed RNAi. Benitec Biopharma is developing treatments for chronic and life-threatening human conditions such as cancer-associated pain, Hepatitis B, Hepatitis C, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec Biopharma has licensed ddRNAi technology to other biopharmaceutical companies for applications including HIV/AIDS and retinitis pigmentosa. For more information on Benitec Biopharma refer to the Company's website at www.benitec.com.